These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8157723)

  • 1. Impaired renal 11 beta-oxidation of 9 alpha-fluorocortisol: an explanation for its mineralocorticoid potency.
    Oelkers W; Buchen S; Diederich S; Krain J; Muhme S; Schöneshöfer M
    J Clin Endocrinol Metab; 1994 Apr; 78(4):928-32. PubMed ID: 8157723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The metabolism of 9 alpha-fluorinated steroids in the human kidney.
    Diederich S; Hanke B; Bähr V; Oelkers W
    Endocr Res; 1996 Nov; 22(4):803-10. PubMed ID: 8969943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism of synthetic corticosteroids by 11 beta-hydroxysteroid-dehydrogenases in man.
    Diederich S; Hanke B; Burkhardt P; Müller M; Schöneshöfer M; Bähr V; Oelkers W
    Steroids; 1998; 63(5-6):271-7. PubMed ID: 9618784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle.
    Stewart PM; Corrie JE; Shackleton CH; Edwards CR
    J Clin Invest; 1988 Jul; 82(1):340-9. PubMed ID: 3164727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cortisol-cortisone shuttle and the apparent specificity of glucocorticoid and mineralocorticoid receptors.
    Edwards CR; Stewart PM
    J Steroid Biochem Mol Biol; 1991 Nov; 39(5B):859-65. PubMed ID: 1659446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The syndrome of apparent mineralocorticoid excess: its association with 11 beta-dehydrogenase and 5 beta-reductase deficiency and some consequences for corticosteroid metabolism.
    Monder C; Shackleton CH; Bradlow HL; New MI; Stoner E; Iohan F; Lakshmi V
    J Clin Endocrinol Metab; 1986 Sep; 63(3):550-7. PubMed ID: 3460996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of glycyrrhizin on cortisol metabolism in humans.
    Soma R; Ikeda M; Morise T; Miyamori I; Takeda R
    Endocr Regul; 1994 Mar; 28(1):31-4. PubMed ID: 7949011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Administration of glycyrrhetinic acid: significant correlation between serum levels and the cortisol/cortisone-ratio in serum and urine.
    Heilmann P; Heide J; Hundertmark S; Schöneshöfer M
    Exp Clin Endocrinol Diabetes; 1999; 107(6):370-8. PubMed ID: 10543414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RU-26988--a new tool for the study of the mineralocorticoid receptor.
    Gomez-Sanchez CE; Gomez-Sanchez EP
    Endocrinology; 1983 Sep; 113(3):1004-9. PubMed ID: 6307658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence that high dose cortisol-induced Na+ retention in man is not mediated by the mineralocorticoid receptor.
    Montrella-Waybill M; Clore JN; Schoolwerth AC; Watlington CO
    J Clin Endocrinol Metab; 1991 May; 72(5):1060-6. PubMed ID: 1850752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism of dexamethasone in the human kidney: nicotinamide adenine dinucleotide-dependent 11beta-reduction.
    Diederich S; Hanke B; Oelkers W; Bähr V
    J Clin Endocrinol Metab; 1997 May; 82(5):1598-602. PubMed ID: 9141556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycyrrhizin induces mineralocorticoid activity through alterations in cortisol metabolism in the human kidney.
    Kageyama Y; Suzuki H; Saruta T
    J Endocrinol; 1992 Oct; 135(1):147-52. PubMed ID: 1431677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mutation in the cofactor-binding domain of 11beta-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension.
    Odermatt A; Dick B; Arnold P; Zaehner T; Plueschke V; Deregibus MN; Repetto H; Frey BM; Frey FJ; Ferrari P
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1247-52. PubMed ID: 11238516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal inactivation, mineralocorticoid generation, and 11beta-hydroxysteroid dehydrogenase inhibition ameliorate the antimineralocorticoid effect of progesterone in vivo.
    Quinkler M; Meyer B; Oelkers W; Diederich S
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3767-72. PubMed ID: 12915667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 11 beta-Hydroxysteroid dehydrogenases: tissue-specific dictators of glucocorticoid action.
    Benediktsson R; Edwards CR
    Essays Biochem; 1996; 31():23-36. PubMed ID: 9078455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cortisol metabolism in healthy young adults: sexual dimorphism in activities of A-ring reductases, but not 11beta-hydroxysteroid dehydrogenases.
    Finken MJ; Andrews RC; Andrew R; Walker BR
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3316-21. PubMed ID: 10487705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Syndrome of apparent mineralocorticoid excess caused by a deficiency of 11 beta-hydroxysteroid dehydrogenase: clinical and genetic study in a Chilean family followed for 19 years].
    Rodríguez JA
    Rev Med Chil; 2000 Jan; 128(1):17-26. PubMed ID: 10883518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of carbenoxolone on the peripheral metabolism of cortisol in human patients.
    Ulick S; Wang JZ; Hanukoglu A; Rösler A
    J Lab Clin Med; 1993 Dec; 122(6):673-6. PubMed ID: 8245686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 11 beta-Hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome.
    Stewart PM; Walker BR; Holder G; O'Halloran D; Shackleton CH
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3617-20. PubMed ID: 8530609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apparent mineralocorticoid excess.
    Benediktsson R; Edwards CR
    J Hum Hypertens; 1994 May; 8(5):371-5. PubMed ID: 8064785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.